2025年4月4日 周五
Home > Archive>Volume 28, Issue 12, 2020 >1048-1053
PDF HTML XML Export Cite reminder
Effects of high-dose iodixanol on renal function in patients with diabetes undergoing percutaneous coronary intervention
CSTR:
[cstr]
Author:
Affiliation:

1.Department of Cardiology, the Second Affiliated Hospital of Army Medical University, PLA, Chongqing 400037, China;2.The 5th People’s Hospital of Chongqing, Chongqing 400062, China;3.The Fuling Central Hospital of Chongqing, Chongqing 408000, China;4.The 9th People’s Hospital of Chongqing, Chongqing 400700, China)

Clc Number:

R5

  • Article
    • | |
  • Metrics
    • |
  • Reference [38]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    Aim To evaluate the effects of high-dose (＞300 mL) iodixanol on renal function of diabetic patients within 72 hours after percutaneous coronary intervention (PCI) . Methods From October 2015 to December 7,7 patients who received high-dose (＞300 mL) iodixanol during PCI in four centers were selected. Finally, 204 cases were enrolled in this study. The incidence of contrast-induced acute kidney injury (CI-AKI) was evaluated. ResultsThe incidence of CI-AKI was 3.9% (8/204). In patients administered 300～500 mL and ＞500 mL iodixanol, the incidence of CI-AKI was 4.3% (7/161) and 2.3% (1/43), respectively. In the subgroup with pre-PCI estimated glomerular filtration rate (eGFR)＜60 mL/(min·1.73 m2), the incidence of CI-AKI was 6.9%(2/29). Multivariate Logistic regression analysis showed independent risk factors for CI-AKI were chronic renal failure, anemia, emergency PCI, and high Mehran score, but not contrast volume. Conclusion The administration of high-dose (＞300 mL) iodixanol in patients with diabetes undergoing PCI does not result in high incidences of post-PCI CI-AKI.

    Reference
    [1] Morcos R, Kucharik M, Bansal P, et al.Contrast-induced acute kidney injury:review and practical update.Clin Med Insights Cardiol, 9,3:1995137820.
    [2] Stacul F, van der Molen AJ, Reimer P, et al.Contrast induced nephropathy:updated ESUR Contrast Media Safety Committee guidelines.Eur Radiol, 1,1(12):2527-2541.
    [3] Kitajima K, Maeda T, Watanabe S, et al.Recent issues in contrast-induced nephropathy.Int J Urol, 1,8(10):686-690.
    [4] Roy AK, Mc Gorrian C, Treacy C, et al.A comparison of traditional and novel definitions (RIFLE, AKIN, and KDIGO) of acute kidney injury for the prediction of outcomes in acute decompensated heart failure.Cardiorenal Med, 3,3(1):26-37.
    [5] Aubry P, Brillet G, Catella L, et al.Outcomes, risk factors and health burden of contrast-induced acute kidney injury:an observational study of one million hospitalizations with image-guided cardiovascular procedures.BMC Nephrology, 6,7(1):167.
    [6] Azzalini L, Candilio L, Mccullough PA, et al.Current risk of contrast-induced acute kidney injury after coronary angiography and intervention:a reappraisal of the literature.Can J Cardiol, 7,3(10):1225-1228.
    [7] Andreucci M, Faga T, Serra R, et al.Update on the renal toxicity of iodinated contrast drugs used in clinical medicine.Drug Healthc Patient Saf, 7,9:25-37.
    [8] Pistolesi V, Regolisti G, Morabito S, et al.Contrast medium induced acute kidney injury:a narrative review.J Nephrol, 8,1(6):797-812.
    [9] Parfrey P.The clinical epidemiology of contrast-induced nephropathy.Cardiovasc Intervent Radiol, 5,8 Suppl 2:S3-S11.
    [10] Mehran R, Nikolsky E.Contrast-induced nephropathy:definition, epidemiology, and patients at risk.Kidney Int, 6,9(100):S11-S15.
    [11] Sato A, Hoshi T, Kakefuda Y, et al.Effect of the Mehran risk score for the prediction of clinical outcomes after percutaneous coronary intervention.J Cardiol, 5,6(5):417-422.
    [12] Mccullough PA, Bertrand ME, Brinker JA, et al.A Meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media.J Am Coll Cardiol, 6,8(4):692-699.
    [13] From AM, Al Badarin FJ, Mcdonald FS, et al.Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy.Circ Cardiovasc Interv, 0,3(4):351-358.
    [14] 陈韵岱, 陈纪言, 傅国胜, 等.碘对比剂血管造影应用相关不良反应中国专家共识.中国介入心脏病学杂志, 4,2(6):341-348.
    [15] Biondi-Zoccai G, Lotrionte M, Thomsen HS, et al.Nephropathy after administration of iso-osmolar and low-osmolar contrast media:evidence from a network meta-analysis.Int J Cardiol, 4,2(2):375-380.
    [16] Reed M, Meier P, Tamhane UU, et al.The relative renal safety of iodixanol compared with low-osmolar contrast media:a Meta-analysis of randomized controlled trials.JACC Cardiovasc Interv, 9,2(7):645-654.
    [17] Davenport MS, Khalatbari S, Cohan RH, et al.Contrast medium-induced nephrotoxicity risk assessment in adult inpatients:a comparison of serum creatinine level-and estimated glomerular filtration rate-based screening methods.Radiology, 3,9(1):92-100.
    [18] Mcdonald JS, Mcdonald RJ, Carter RE, et al.Risk of intravenous contrast material-mediated acute kidney injury:a propensity score-matched study stratified by baseline-estimated glomerular filtration rate.Radiology, 4,1(1):65-73.
    [19] Aspelin P, Aubry P, Fransson SG, et al.Nephrotoxic effects in high-risk patients undergoing angiography.N Engl J Med, 3,8(6):491-499.
    [20] Solomon RJ, Natarajan MK, Doucet S, et al.Cardiac angiography in renally impaired patients (CARE) study:a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.Circulation, 7,5(25):3189-3196.
    [21] Hardiek KJ, Katholi RE, Robbs RS, et al.Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography.J Diabetes Complicat, 8,2(3):171-177.
    [22] Juergens CP, Winter JP, Nguyen-Do P, et al.Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention:a randomized trial.Intern Med J, 9,9(1):25-31.
    [23] Nie B, Cheng WJ, Li YF, et al.A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs.iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.Catheter Cardiovasc Interv, 8,2(7):958-965.
    [24] Han XF, Zhang XX, Liu KM, et al.Contrast-induced nephropathy in patients with diabetes mellitus between iso-and low-osmolar contrast media:a Meta-analysis of full-text prospective, randomized controlled trials.PLoS One, 8,3(3):e194330.
    [25] Zhang J, Jiang Y, Rui Q, et al.Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI.Medicine (Baltimore), 8,7(18):e617.
    [26] Neumann FJ, Sousa-Uva M, Ahlsson A, et al.2018 ESC/EACTS guidelines on myocardial revascularization.The task force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)].G Ital Cardiol (Rome), 9,0(7-8 Suppl 1):1S-61S.
    [27] Detrenis S, Meschi M, Musini S, et al.Lights and shadows on the pathogenesis of contrast-induced nephropathy:state of the art.Nephrol Dial Transplant, 5,0(8):1542-1550.
    [28] 李华珍, 王红, 梁文武.冠状动脉介入术导致对比剂肾病危险因素分析.中国动脉硬化杂志, 1,9(6):529-532.
    [29] Vlachopanos G, Schizas D, Hasemaki N, et al.Pathophysiology of contrast-induced acute kidney injury (CIAKI).Curr Pharm Des, 9,5(44):4642-4647.
    [30] Feldkamp T, Baumgart D, Elsner M, et al.Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients.Clin Nephrol, 6,6(5):322-330.
    [31] Tumlin J, Stacul F, Adam A, et al.Pathophysiology of contrast-induced nephropathy.Am J Cardiol, 6,8(6A):14K-20K.
    [32] Persson PB, Hansell P, Liss P.Pathophysiology of contrast medium-induced nephropathy.Kidney Int, 5,8(1):14-22.
    [33] Keaney JJ, Hannon CM, Murray PT.Contrast-induced acute kidney injury:how much contrast is safe?.Nephrol Dial Transplant, 3,8(6):1376-1383.
    [34] Seeliger E, Sendeski M, Rihal CS, et al.Contrast-induced kidney injury:mechanisms, risk factors, and prevention.Eur Heart J, 2,3(16):2007-2015.
    [35] Seeliger E, Lenhard DC, Persson PB.Contrast media viscosity versus osmolality in kidney injury:lessons from animal studies.Biomed Res Int, 4,4:358136.
    [36] Dawson P, Howell M.The non-ionic dimers:a new class of contrast agents.Br J Radiol, 6,9(706):987-991.
    [37] Levine GN, Bates ER, Blankenship JC, et al.2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention.a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions.J Am Coll Cardiol, 1,8(24):e44-e122.
    [38] Wi J, Ko YG, Kim JS, et al.Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention.Heart, 1,7(21):1753-1757.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

ZHAO Ning, CHEN Zaiyan, WANG Zhe, XU Qiang, ZHOU Yinpin, XU Zhonglin, SONG Yaoming, JIN Jun, HUANG Lan, ZHAO Xiaohui. Effects of high-dose iodixanol on renal function in patients with diabetes undergoing percutaneous coronary intervention[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2020,28(12):1048-1053.

Copy
Share
Article Metrics
  • Abstract:532
  • PDF: 695
  • HTML: 0
  • Cited by: 0
History
  • Received:January 01,2020
  • Revised:February 19,2020
  • Online: December 14,2020
Article QR Code

You are the 27263 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025